Avigail Lab Meditech Group Ltd
About
Avigail Lab Meditech Group is an Israeli biotech SME developing Marine BioVenom, a biological anti-cancer drug candidate derived from jellyfish venom (Rhopilema nomadica). The programme has shown feasibility in four cancer types (liver, pancreatic, lung and breast), with liver cancer as the lead indication. It is currently at the animal research stage. We use a special delivery system for the active components. Our team includes academic researchers and a pharmacist founder.
Representatives
CEO, Owner & Founder
Avigail Lab Meditech Group Ltd